Clinical Trial Update: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MK0822 for prolonging time to first bone metastasis in men with castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• MK0822

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostate Cancer | Phase 3 | Status: WITHDRAWN